El Husseiny Noha M, Fahmy Hala M, Mohamed Waleed A, Amin Hisham H
Noha M El Husseiny, Hala M Fahmy, Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo 11111, Egypt.
World J Hepatol. 2012 Aug 27;4(8):242-7. doi: 10.4254/wjh.v4.i8.242.
To assess vitamin D in hepatitis C patients and its relationship to interleukin (IL)-23, IL-17, and macrophage chemoattractant protein-1 (MCP-1).
The study was conducted on 50 Egyptian hepatitis C virus (HCV) genotype number IV-infected patients and 25 age- and gender-matched healthy subjects. Venous blood samples were obtained. Samples were allowed to clot and sera were separated by centrifugation and stored at -20 °C. A 25 hydroxy vitamin D assay was carried out using solid phase RIA. A 1,25 dihydroxy vitamin D assay was carried out using a commercial kit purchased from Incstar Corporation. IL-17 and -23 and MCP-1 were assayed by an enzyme immunoassay. Quantitative and qualitative polymerase chain reaction for HCV virus were done by TaqMan technology. Only HCV genotype IV-infected subjects were included in the study. The mean ± SD were determined, a t-test for comparison of means of different parameters was used. Correlation analysis was done using Pearson's correlation. Differences among different groups were determined using the Kruskal-Wallis test.
The mean vitamin D level in HCV patients (group I) was 15 ± 5.2 ng/mL while in control (group II) was 39.7 ± 10.8. For active vitamin D in group I as 16.6 ± 4.8 ng/mL while in group II was 41.9 ± 7.9. IL-23 was 154 ± 97.8 in group I and 6.7 ± 2.17 in group II. IL-17 was 70.7 ± 72.5 in cases and 1.2 ± 0.4 in control. MCP-1 was 1582 ± 794.4 in group I and 216.1 ± 5.38 in group II. Vitamin D deficiency affected 72% of HCV-infected patients and 0% of the control group. Vitamin D insufficiency existed in 28% of HCV-infected patients and 12% of the control group. One hundred percent of the cirrhotic patients and 40% of non cirrhotic HCV-infected patients had vitamin D deficiency. IL-23, IL-17, and MCP-1 were markedly increased in HCV-infected patients in comparison to controls.A significant negative correlation between vitamin D and IL-17 and -23 and MCP-1 was detected. HCV-infected males and females showed no differences with respect to viral load, vitamin D levels, IL-17, IL-23 and MCP-1. The viral load was negatively correlated with vitamin D and active vitamin D (P = 0.0001 and P = 0.001, respectively), while positively correlated with IL-23, IL-17, and MCP-1. We classified the patients according to sonar findings into four groups. Group Ia with bright hepatomegaly and included 14 patients. Group Ib with perihepatic fibrosis and included 11 patients. Group Ic with liver cirrhosis and included 11 patients. Group Id with hepatocellular carcinoma (HCC) and included 14 patients. Vitamin D and active vitamin D were shown to be lower in cirrhotic patients and much lower in patients with HCC, and this difference was highly significant (P = 0.0001). IL-17 and -23 and MCP-1 were higher in advanced liver disease) and the differences were highly significant (P = 0.0001).
Whether the deficiency of vitamin D is related to HCV-induced chronic liver disease or predisposing factor for higher viral load is a matter of debate.
评估丙型肝炎患者体内的维生素D及其与白细胞介素(IL)-23、IL-17和巨噬细胞趋化蛋白-1(MCP-1)的关系。
对50例感染丙型肝炎病毒(HCV)基因IV型的埃及患者和25例年龄及性别匹配的健康受试者进行研究。采集静脉血样本。样本待其凝固后,通过离心分离血清并储存于-20°C。采用固相放射免疫分析法进行25羟维生素D检测。使用从英斯达公司购买的商业试剂盒进行1,25二羟维生素D检测。通过酶免疫分析法检测IL-17、IL-23和MCP-1。采用TaqMan技术对HCV病毒进行定量和定性聚合酶链反应。本研究仅纳入HCV基因IV型感染的受试者。测定均值±标准差,采用t检验比较不同参数的均值。使用Pearson相关性进行相关性分析。采用Kruskal-Wallis检验确定不同组间的差异。
HCV患者(I组)的维生素D平均水平为15±5.2 ng/mL,而对照组(II组)为39.7±10.8 ng/mL。I组活性维生素D为16.6±4.8 ng/mL,II组为41.9±7.9 ng/mL。I组IL-23为154±97.8,II组为6.7±2.17。病例组IL-17为70.7±72.5,对照组为1.2±0.4。I组MCP-1为1582±794.4,II组为216.1±5.38。维生素D缺乏影响72%的HCV感染患者,而对照组为0%。28%的HCV感染患者存在维生素D不足,对照组为12%。100%的肝硬化患者和40%的非肝硬化HCV感染患者存在维生素D缺乏。与对照组相比,HCV感染患者的IL-23、IL-17和MCP-1显著升高。检测到维生素D与IL-17、IL-23和MCP-1之间存在显著负相关。HCV感染的男性和女性在病毒载量、维生素D水平、IL-17、IL-23和MCP-1方面无差异。病毒载量与维生素D和活性维生素D呈负相关(分别为P = 0.0001和P = 0.001),而与IL-23、IL-17和MCP-1呈正相关。根据超声检查结果将患者分为四组。Ia组为肝脏肿大且回声增强,包括14例患者。Ib组为肝周纤维化,包括11例患者。Ic组为肝硬化,包括11例患者。Id组为肝细胞癌(HCC),包括14例患者。肝硬化患者的维生素D和活性维生素D较低,HCC患者更低,且差异具有高度显著性(P = 0.0001)。晚期肝病患者的IL-17、IL-23和MCP-1较高,差异具有高度显著性(P = 0.0001)。
维生素D缺乏是与HCV诱导的慢性肝病相关,还是病毒载量升高的易感因素,尚有争议。